SBSaeed Bohlega

Saeed Bohlega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saeed Bohlega has a total of 303 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond Oral Levodopa: Advanced Dopaminergic Delivery, Device-Assisted Therapies, and Treatment Sequencing in Parkinson’s Disease — Evidence and Implementation Priorities for the GCC

    by Isa Ahmed Alsharoqi, Mohamed Elmahdy, Saeed A. Bohlega

    Background: Advanced Parkinson’s disease (PD) therapies offer increasingly diverse ways to control motor complications, but evidence defining comparative sequences and sustainable Gulf Cooperation Council (GCC) delivery remains limited. Objective: To appraise advanced therapies, distinguish established benefit from uncertain positioning, and propose a practical framework for referral, selection and regional implementation. Evidence acquisition: This critical narrative review used targeted retrieval of clinical studies, guidance, regulatory documents and regional sources, with a publication cut-off of 8 November 2026 and revision verification on 9 November and additional citation checks on 12 November 2026. Appraisal addressed comparator, population, endpoint, attrition, treatment burden and applicability. No meta-analysis or formal consensus process was undertaken. Evidence synthesis: Controlled infusion trials generally showed OFF-time differences of approximately 1.4–1.9 hours/day, but heterogeneous comparators and selected populations prevent treatment ranking. Conventional deep brain stimulation has substantial randomised evidence; adaptive systems require algorithm- and patient-specific interpretation. Focused ultrasound demands target-specific assessment of irreversible and cumulative risks. Regional cohorts document selected-centre experience, while national access remains incompletely verified. Cardiometabolic and cognitive vulnerability, language, care-partner capacity, Ramadan medication timing and continuity of funding or support modify implementation. GCC-PD ADVANCE links six decision domains to parallel documentation of clinically preferred and feasible care, explicit escalation and measurable follow-up. Conclusions: Timely evaluation and individualised selection should connect responsive symptoms with acceptable burden and sustainable care. GCC-PD ADVANCE is an author-proposed framework requiring stakeholder refinement and prospective evaluation; it does not establish a validated therapeutic hierarchy.

  • Open Access

    The GCC MS Genetics Ancestry Blind Spot: A Four-Domain Taxonomy, Six-Country Evidence-Gap Map, and Proposed Closure Indicators

    by Isa A. Alsharoqi, Abdulla I. Salem Alsharoqi, Saeed A. Bohlega

    Background: Arab and Gulf Cooperation Council (GCC) populations remain poorly characterized in multiple sclerosis (MS) genomics despite advances in global multi-ancestry discovery. Previous regional reviews describe available associations, while a related commentary addresses clinical implementation. The present study asks a different question: which specific evidence deficits constitute the GCC MS Genetics Ancestry Blind Spot, and how could progress in closing them be documented? Objectives: To formalize a four-domain evidence-gap taxonomy; map published GCC findings across six countries and distinct evidentiary layers; distinguish absence of retrieval from absence of biological evidence; and propose transparent, denominator-based indicators for future regional assessment. Methods: A benchmark-informed narrative and conceptual synthesis reinterpreted the authors’ previously published 14-study GCC scoping evidence map in light of selected peer-reviewed MS ancestry studies published through 5 November 2026, the 2025 Arab pangenome, and documented regional genomic resources. Evidence was categorized as reported susceptibility association, exploratory/familial or molecular observation, contextual population-genomics resource, or study not identified within the cited corpus. No new systematic search, pooled MS-wide ancestry proportion, or validation exercise was claimed. Results: The 2019 IMSGC map included 47,429 cases and 68,374 controls; two September 2026 studies expanded multi-ancestry analyses but did not report Arab/GCC participants as major explicit strata. The approximately 0.17% Arab GWAS Catalog benchmark is cross-disease, not MS-specific. GCC evidence was heterogeneous: a Saudi high-resolution HLA study reported an HLA-DRB1*15:01 association, Bahrain provided small low-resolution HLA and downstream molecular observations, Kuwait contributed targeted non-HLA and vitamin D-pathway studies, and Saudi Arabia also supplied familial/mitochondrial data. Historical Omani HLA testing and an Abu Dhabi familial series do not establish validated genomic prediction. A six-country matrix and proposed indicators specify what is observable, missing, or unverified without assigning unsupported country rankings. Conclusions: The ancestry blind spot is best treated as four separately auditable evidence deficits—representation, genetic architecture, prediction validity, and contextual ascertainment. A denominator-defined monitoring framework, not another clinical-implementation pathway, provides the distinctive contribution and a testable agenda for multicountry GCC MS genomics.

  • Open Access

    Treatment Exit in Aging Multiple Sclerosis: A Critical Review of Discontinuation, De-Escalation, and Dose Reduction, with Implications for GCC Practice

    by Isa A. Alsharoqi, Abdulla I Salem Alsharoqi, Sayed Mohamed Alsaffar, Saeed A Bohlega

    Background: Aging and prolonged disease stability prompt reassessment of multiple sclerosis disease-modifying therapy. Discontinuation, switching, dose reduction and interval extension are distinct strategies. Stability during treatment may reflect reduced inflammatory activity, continuing drug effects, or both; chronological age alone cannot establish that withdrawal will preserve control. Objective: To critically assess treatment-exit evidence, reconcile apparently conflicting findings, distinguish treatment effects from prognostic associations, and examine implications for Gulf Cooperation Council (GCC) practice. Approach: A targeted, web-assisted critical narrative review examined accessible primary studies, corrections, conference reports, trial registrations and regional documents through 1 November 2026. Comparisons considered population, mechanism, strategy, outcome, surveillance, residual exposure, restart and alignment of follow-up. No meta-analysis, independent duplicate screening or formal certainty grading was performed. Principal findings: In DISCOMS, new disease activity occurred in 12.2% of discontinuers versus 4.7% of continuers over two years: an absolute difference of 7.5 percentage points (95% confidence interval, 0.6–15.0); non-inferiority was not established. DOT-MS stopped early after significant inflammatory activity in 8/45 discontinuers versus 0/44 continuers. Differences in eligibility, MRI thresholds and follow-up prevent attribution of these findings to age alone. Selected older-adult cohorts report limited relapse activity, but disability and patient-reported outcomes remain less certain. Natalizumab and fingolimod cessation carry early reactivation concerns requiring explicit consideration of the subsequent treatment pathway. Anti-CD20 cessation studies show sustained suppression in some selected populations, although residual exposure, treatment selection and imprecision limit conclusions about durable treatment independence. The included evidence does not establish a reliable comparative reduction in serious infection following treatment exit. Lower-efficacy switching can increase recurrence, while findings for specified extended intervals cannot be generalized to arbitrary dose reductions. Kuwait supplies direct natalizumab interval-extension evidence in younger adults; other GCC cohorts mainly inform treatment context. Regional guidance offers practical criteria that require appraisal against primary evidence and local monitoring conditions. Conclusions: Treatment reassessment should compare specified alternatives with continuation, communicate relevant absolute outcomes and uncertainty, and distinguish estimated benefit–harm from regional applicability. An author-proposed framework organizes patient goals, reasons for change, inflammatory activity, disability trajectory, exposure, harms, observation and reassessment. Its accompanying minimum dataset supports prospective evaluation without assigning a risk score or universal stopping threshold. Neither the framework’s feasibility nor its clinical utility has been validated. Mechanism-specific comparative studies and coordinated GCC research should evaluate inflammatory recurrence, disability, serious infections, treatment burden and continuity of care. Such evaluation should distinguish elective reassessment from treatment interruptions caused by changing access arrangements.

  • Open Access

    Beyond a Decade of MENACTRIMS: Scientific Achievements, Publicly Documented Implementation Gaps, and a Roadmap to a Regional Learning Health System

    by Isa Ahmed Alsharoqi, Saeed A. Bohlega

    Background: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) has developed congresses, clinical guidance, registry research, training, certification, and advocacy partnerships. Evaluating this infrastructure requires distinctions between organizational activity, implementation, and attributable benefit.Objectives: To characterize documented achievements, compare the geographic distribution of major functions, identify public reporting gaps, and propose a measurable regional learning-health-system roadmap.Methods: A structured public-document audit and targeted literature synthesis covered activities from 2014 through 23 August 2026, with a documented update on 16 October 2026. Sources were classified by provenance and evidentiary purpose, without performance scoring. Geographic coverage used a fixed 19-jurisdiction Middle East and North Africa frame. Reported attendance terms and registry denominators were preserved.Results: Ten completed congresses were identified; seven with exact headline attendance had a median of 934 participants (interquartile range 761.5–1006.5). Seven congresses were hosted in the United Arab Emirates. Five major guideline outputs or revisions, multicountry registry studies, policy endorsements, and traceable grant- and fellowship-linked publications demonstrated sustained scientific activity. The public registry headline was 15,387, compared with 14,438 enumerable center records; variable displays represented 78.8%–93.9% of the headline, without establishing true field completeness. Iran, Egypt, and Kuwait contributed 75.4% of enumerable records. Council listings covered 15/19 jurisdictions, registry centers 8/19, and certified centers 2/19. Certification standards already specify three-year renewal and prefer registry participation; fellowship terms require reporting and career follow-up. Aggregated results of these processes were less readily ascertainable.Conclusions: MENACTRIMS has established substantial regional infrastructure. Differing geographic distributions identify questions about coordination and opportunity but do not establish organizational failure. A phased roadmap for 2027–2035 should build on existing systems through denominator reconciliation, publicly reported program outcomes, guideline-linked quality improvement, and meaningful patient and professional participation. Public-source limitations and the non-systematic synthesis preclude causal attribution of regional patient outcomes to MENACTRIMS.

  • Open Access

    Anti-CD20 Therapy Within the Early High-Efficacy Treatment Paradigm in GCC Multiple Sclerosis: Evidence, Clinical Positioning, and a Regional Treatment-Sequencing Framework

    by Isa A. Alsharoqi, Abdulla I. Salem Alsharoqi, Saeed A. Bohlega

    Background: Anti-CD20 monoclonal antibodies are central to high-efficacy multiple sclerosis (MS) care. Across the six Gulf Cooperation Council (GCC) states, clinical value also depends on infection prevention, reproductive planning, delivery capacity, mixed public-private coverage, tender continuity, biosimilar governance, and registry maturity. Objectives: To map anti-CD20 efficacy, safety, real-world, reproductive, pharmacoeconomic, access, biosimilar, and implementation evidence, and translate it into a GCC treatment-sequencing and monitoring framework. Methods: PubMed/MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, Google Scholar, registries, regulatory sources, conference materials and relevant grey literature were searched through 8 July 2026. Two reviewers screened titles/abstracts and full-text reports independently and resolved disagreements by consensus, as described in the original review methods. A targeted evidence update through 13 October 2026 informed clinical interpretation without changing the original review counts. Results: Searches identified 1,870 records; 550 duplicates were removed, 1,320 records screened, 270 full-text reports assessed and 95 sources included. Pivotal and extension studies support the anti-inflammatory efficacy of ocrelizumab, ofatumumab and ublituximab. OVERLORD-MS adds randomized head-to-head MRI non-inferiority evidence for rituximab versus ocrelizumab. The October evidence update includes a seven-country MENACTRIMS rituximab cohort (n = 774), a Kuwaiti high-efficacy treatment cohort (n = 1,408), additional immunoglobulin and safety data, and emerging Saudi and UAE clinical reports. GCC implementation priorities include treatment continuity, affordability, reproductive care, biosimilar governance and registry development [80–88]. Conclusions: The proposed framework positions anti-CD20 therapy selectively within early high-efficacy care, integrating inflammatory risk, agent-specific evidence and safety, reproductive planning, route preference, access continuity, biosimilar traceability, and registry capture. OVERLORD-MS strengthens rituximab’s comparative evidence but does not establish class-wide interchangeability. Prospective multicountry GCC validation remains necessary.

  • Open Access

    Calcitonin Gene-Related Peptide-Targeted Migraine Prevention in the Gulf Cooperation Council: A Structured Evidence Review of Guidelines, Access, and Patient-Stratified Care

    by Isa Ahmed Alsharoqi, Abu-Baker Almadani, Abdulla I. Salem Alsharoqi, Saeed A. Bohlega

    International guidance increasingly permits calcitonin gene-related peptide (CGRP)-targeted therapies to be considered at the initial preventive-treatment decision, but clinical eligibility does not ensure registration, reimbursement, practical access, or first prescribing. We reviewed contemporary preventive evidence and used the six Gulf Cooperation Council (GCC) health systems as a regional test case for this evidence-to-access gap. This structured evidence review used a focused PubMed/MEDLINE working set of 2,443 records through September 1, 2026, complementary bibliographic and trial-registry searches, professional guidance, and targeted GCC regulatory, procurement, and real-world sources. Prioritized assessment included 248 full texts and a 135-document working evidence corpus. A targeted update on September 29, 2026 checked for additional major guidance and head-to-head evidence without altering the original numerical workflow. Network meta-analyses support efficacy across several established and CGRP-targeted preventives but do not establish a simple class hierarchy. In their respective trials, HER-MES and TEMPLE reported lower adverse-event discontinuation and higher at least 50% responder rates with erenumab and atogepant than with topiramate; their populations and single-comparator designs limit generalization to universal first-treatment superiority. AAN/AHS 2026 emphasizes individualized choice; NICE and 2026 BASH guidance illustrate how national access pathways can remain sequential. Public GCC evidence is uneven, with the clearest clinical and regulatory documentation in the United Arab Emirates, Saudi Arabia, and Kuwait and important transparency gaps elsewhere. We therefore propose a five-layer implementation audit separating scientific eligibility, regulatory availability, clinical preference, reimbursement/formulary eligibility, and actual prescribing. The resulting patient-stratified framework preserves conventional-first, CGRP-targeted-first, and phenotype/comorbidity-driven pathways. The principal implication is not universal CGRP-first prescribing, but explicit separation of evidence-based choice from health-system access rules, with outcome-based reassessment and country-specific economic evaluation.

  • Open Access

    Beyond Fixed Intervals: Biomarker-Gated Anti-CD20 Therapy in Multiple Sclerosis—Defining CD19/CD20 Gating, Immunoglobulin Monitoring and a Gulf Cooperation Council Framework

    by Isa A. Alsharoqi, Abdulla I. Salem Alsharoqi, Saeed A. Bohlega

    Background: Anti-CD20 therapies provide strong suppression of inflammatory multiple sclerosis (MS), but prolonged exposure raises concerns about immunoglobulin depletion, infection and impaired vaccine responses.Objectives: To critically evaluate biomarker-informed maintenance dosing and propose an implementation framework for the Gulf Cooperation Council (GCC).Methods: A targeted narrative review examined indexed publications, trial registries, prescribing information and accessible conference reports through 27 September 2026. Randomised evidence, observational findings and proposed practice were distinguished.Key findings: Selected ocrelizumab and rituximab cohorts retain inflammatory control during extended intervals despite peripheral B-cell return. Randomised calendar-extension findings and preliminary B-cell-tailored trial observations support further evaluation but do not validate a universal threshold or the integrated BGAT strategy. Higher-dose ocrelizumab did not improve disability outcomes; this does not establish the equivalence of reduced exposure. Infection risk reflects immunoglobulin trajectories, cumulative treatment, disability and comorbidity. Biomarker-triggered ofatumumab and ublituximab dosing remain insufficiently studied.Proposed framework: Biomarker-Gated Anti-CD20 Therapy (BGAT) combines a depletion/repopulation gate, an immunoglobulin-and-infection safety gate and a clinical/MRI override. Laboratory validation, agent-specific eligibility and shared decisions are prerequisites. A GCC pathway links tiered laboratory capacity, prospective registry capture and a multicentre validation study.Conclusions: BGAT requires prospective validation against both standard dosing and simpler extended calendar schedules. Success requires preserved inflammatory and disability outcomes, acceptable immune safety and demonstrable value to patients and health systems.

  • Open Access

    Success and Failure in Progressive Multiple Sclerosis Trials: Mechanism-Population-endpoint Alignment and Priorities for Progressive MS Research in the Arabian Gulf

    by Isa Ahmed Alsharoqi, Abdulla I Salem Alsharoqi, Saeed A Bohlega

    Background: Progressive multiple sclerosis (MS) presents a persistent translational challenge: credible biological activity has often failed to produce confirmed disability benefit. Contemporary trials offer contrasting tests of therapeutic mechanism, population selection, and outcome measurement, with direct implications for research participation in the Gulf Cooperation Council (GCC). Methods: This structured comparative review combined reproducible PubMed retrieval with purposive selection of 46 programme entries and targeted verification of publications, trial records, and regulatory assessments through 6 September 2026. Primary results, secondary findings, and interpretive constraints were extracted separately. A regional search informed a protocol-linked GCC dataset. Heterogeneous comparisons were synthesized without pooling; independent comprehensive screening and formal outcome-level appraisal were not completed. Results: ORATORIO, EXPAND, and HERCULES established disability benefit in defined populations. Contrasting findings from PERSEUS, GAVOTTE, and MS-STAT2 limited extrapolation across phenotypes, exposure strategies, and imaging outcomes. ORATORIO-HAND extended positive evidence to broader primary progressive MS eligibility, whereas FENtrepid reported active-comparator noninferiority. Participant-level analyses supported the clinical relevance of walking and hand-function deterioration, while treatment-effect detection remained dependent on component contributions. Regulatory assessments demonstrated that efficacy, population-specific certainty, and serious liver injury jointly determine therapeutic translation. Regional sources documented research infrastructure but did not establish protocol-specific recruitment capacity. The synthesis generated four testable hypotheses and a 40-field GCC dictionary with an eligibility-critical core. Conclusions: Progressive-MS development requires evidence connecting relevant target engagement, a clinically characterized population, meaningful functional preservation, and acceptable risk. This framework converts contrasting trial results into prospective design questions and gives GCC centres a practical basis for testing recruitment readiness and the applicability of international evidence.

  • Open Access

    The Vitamin D–Multiple Sclerosis Paradox in the Arabian Gulf: A Critical Synthesis of Lifestyle Transition, Genetic Susceptibility, and Gene–Environment Interactions

    by Isa Ahmed Alsharoqi, Saeed A. Bohlega

    Background: Gulf Cooperation Council (GCC) populations combine intense ultraviolet B (UVB) radiation with widespread hypovitaminosis D and multiple sclerosis (MS) burden. We examine this Arabian Gulf vitamin D–MS paradox as an exposure–biology–inference problem rather than a single causal pathway. Methods: We conducted a structured narrative review and regional synthesis using a structured search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and regional sources (January 1990–August 2026), followed by a targeted September 2026 update incorporating the Bahrain Research Square preprint. Evidence was appraised for ascertainment, assay heterogeneity, temporality, confounding, ancestry transferability, replication, and intervention design. Results: Low 25-hydroxyvitamin D [25(OH)D] recurs across the GCC despite abundant UVB. In Bahrain, mean 25(OH)D was lower during April–September than October–March (21.1±17.4 vs 34.7±21.2 nmol/L); secondary calculation gave a difference of −13.6 nmol/L (95% CI −17.3 to −9.9; Cohen’s d=0.72). A September 2026 preprint identified 876 actively followed Bahraini patients, corresponding to crude registry-based prevalence of 117.2 per 100,000 (95% CI 109.4–125.0), and 48 new diagnoses during March 2025–March 2026, yielding incidence of 6.4 per 100,000 (95% CI 4.7–8.5). Centralized national referral and DMT delivery support high completeness of the contemporary clinical numerator, while denominator projection and lack of age/sex standardization remain limitations. Regional genetic, EBV, obesity, smoking, diagnostic-era, and treatment-related evidence supports a multifactorial model. Conclusions: Vitamin D is a plausible modifiable component of multifactorial MS susceptibility, not a stand-alone explanation for GCC epidemiological change. Deficiency should be corrected for general health, but no MS-specific serum target or lifelong high-dose regimen is established. Contemporary Bahrain data strengthen evidence of substantial national MS burden while showing that higher prevalence need not imply a proportional rise in annual incidence. Ancestry-aware longitudinal GCC studies are needed.

  • Open Access

    Measuring What Matters in Progressive Multiple Sclerosis: Beyond Disability Scores-Global Evidence and an Arabian Gulf Perspective

    by Isa Ahmed Alsharoqi, Bader Ali Mohamed, Abdulla I Salem Alsharoqi, Saeed A Bohlega

    Background: Progressive multiple sclerosis (MS) requires outcomes that represent consequential deterioration and support valid treatment comparisons. Broader domain coverage, high reliability, and more progression events address different aspects of endpoint performance. Objectives: To evaluate established and emerging outcomes, distinguish progression ascertainment from randomized treatment discrimination, and derive a practical Gulf Cooperation Council (GCC) monitoring dataset. Methods: Targeted public retrieval through 8 September 2026 supported a purposive synthesis of 19 randomized trial programmes, linked measurement and composite-endpoint studies, existing outcome frameworks, and regional publications. Measurement properties and randomized treatment discrimination were examined separately. Within-trial comparisons preserved effect measures, confirmation periods, and analytical status. The review did not undertake exhaustive database searching, independent duplicate review, or de novo comparative pooling. Results: EDSS-primary trials established treatment benefits in several progressive-MS populations, while performance measures revealed complementary domain information. ASCEND had a negative primary composite but a substantial secondary dexterity signal (9HPT odds ratio 0.56, 95% CI 0.40–0.80). ORATORIO-HAND prospectively demonstrated benefit on EDSS-or-9HPT progression (hazard ratio 0.70, 95% CI 0.57–0.86). Neither result establishes universal composite superiority. Measurement studies showed that high reliability can coexist with detectable-change boundaries exceeding commonly used progression thresholds. Contemporary composite analyses further distinguish broader event capture from stronger treatment contrasts, and OR-type from AND-type definitions. A four-level architecture integrates neurological disability, domain performance, patient-relevant function, and biological or digital observations. Building on existing outcome sets and registry infrastructure, the proposed GCC dataset separates baseline information, eight routine assessment modules, conditional investigations and confirmation, and optional extensions. Conclusions: Endpoint adequacy is specific to the population, construct, measurement process, and estimand. Harmonized, dated multidomain observations can strengthen progression assessment without assuming that every added measure improves statistical power. The GCC proposal provides an evidence-derived specification for prospective feasibility and clinical-utility evaluation.